News from LSU Health Shreveport

The LSU Health Shreveport Department of Molecular & Cellular Physiology and Aphios Corporation have obtained Patent.

The LSU Health Shreveport Department of Molecular & Cellular Physiology and Aphios Corporation have obtained United States Patent No. 9,994,585 entitled “Transplantation Therapies,” for marine pharmaceutical ‘Bryostatin-1,’ which will be used as an additive to organ transport and storage solutions.

The use of this additive may allow more organs to be made usable for transplantation by making marginal, or substandard, organs survive where they would not have before. Currently, many organs are not ultimately usable in transplantation and are considered less than ideal because they have exceeded the amount of time beyond which the organ would undergo failure. The current
patent technology specifically blocks the mechanisms through which the body attacks the graft to prevent acute transplant failure. This innovative approach will have far-reaching impact on the entire transplantation industry.

J. Steven Alexander, PhD, Professor of Molecular & Cellular Physiology and Medicine at LSU Health Shreveport, working with April Carpenter Elrod, PhD, Assistant Professor of Health and Exercise Physiology at Ursinus College in Collegeville, Penn.,
and Dr. Trevor Castor at Aphios Corporation in Woburn, Mass., discovered that the treatment of blood vessels with Bryostatin-1, a compound derived from the marine bryozoans species Bugula neritina, stabilizes blood vessel cells called  ‘endothelial’ cells allowing them to stop the infiltration by white cells, which should lead to better organ survival and many more organs being available. This will allow more organs to now be safely shipped trans-nationally and even internationally. Also important is that this drug does not need to be given to the recipient, but rather is only introduced to the donor organ during cold storage.

“The approach is nothing less than revolutionary and before very long we hope that it will be widely used as a main transplant solution,” said Dr. J. Steven Alexander about the new use patent.

Previously, Bryostatin-1 was researched for treating cancer, for which it is not highly active, but consequently, has extensive human safety data.

Share our News with your friends on Facebook, Twitter, and more! Just click the icon at the end of the news story to share.